← back to search

John M. Lachin

Milken Institute · US
Area of research
Endocrinology, Diabetes and Metabolism · Statistics and Probability
Research interest
Research interests include Diabetes Management and Research, Diabetes Treatment and Management, Statistical Methods in Clinical Trials, and Diabetes and associated disorders.
h-index
100
citations
55,334
works
518
NIH funding
primary concept
Medicine
email

Recent publications

Differential Longitudinal Effects of Glucose-Lowering Medications on Glucagon and C-peptide Responses in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study (GRADE).
2026cited by 0position: contributordoi
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes
Diabetes 2024cited by 31position: middledoi
Evidence for C-Peptide as a Validated Surrogate to Predict Clinical Benefits in Trials of Disease-Modifying Therapies for Type 1 Diabetes.
2024cited by 23position: contributordoi
Neuropathic Pain With and Without Diabetic Peripheral Neuropathy in Type 1 Diabetes.
2024cited by 9position: contributordoi
Diabetes Risk Factors and Bone Microarchitecture as Assessed by High-Resolution Peripheral Quantitative Computed Tomography in Adults With Long-standing Type 1 Diabetes.
2024cited by 7position: contributordoi
Association of Baseline Factors With Glycemic Outcomes in GRADE: A Comparative Effectiveness Randomized Clinical Trial.
2024cited by 7position: contributordoi
Relationship Between Average Glucose Levels and HbA1c Differs Across Racial Groups: A Substudy of the GRADE Randomized Trial.
2024cited by 6position: contributordoi
History of the Diabetes Control and Complications Trial and Its Follow-up Epidemiology of Diabetes Interventions and Complications Study: Studies That Changed the Treatment of Type 1 Diabetes.
2024cited by 5position: contributordoi
Response to Comment on Lachin et al. Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial. Diabetes Care 2022;45:2445-2448.
2023cited by 0position: contributordoi
Risk factors for lower bone mineral density in older adults with type 1 diabetes: a cross-sectional study
The Lancet Diabetes & Endocrinology 2022cited by 62position: middledoi
Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study
Diabetes Care 2022cited by 28position: middledoi
Plasma advanced glycation end products and the subsequent risk of microvascular complications in type 1 diabetes in the DCCT/EDIC.
2022cited by 26position: contributordoi
Biochemical Markers of Bone Turnover in Older Adults With Type 1 Diabetes
The Journal of Clinical Endocrinology & Metabolism 2022cited by 26position: middledoi
Continuous Glucose Monitoring in Adults With Type 1 Diabetes With 35 Years Duration From the DCCT/EDIC Study.
2022cited by 25position: contributordoi
Brain Structure Among Middle-aged and Older Adults With Long-standing Type 1 Diabetes in the DCCT/EDIC Study.
2022cited by 22position: contributordoi
Relationships Between the Cumulative Incidences of Long-term Complications in Type 1 Diabetes: The DCCT/EDIC Study
Diabetes Care 2022cited by 20position: middledoi
Association of Estimated Time-in-Range Capillary Glucose Levels Versus HbA1c With Progression of Microvascular Complications in the Diabetes Control and Complications Trial.
2022cited by 13position: contributordoi
Physical Function in Middle-aged and Older Adults With Type 1 Diabetes: Long-term Follow-up of the Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications Study.
2022cited by 10position: contributordoi
Optimal Frequency of Urinary Albumin Screening in Type 1 Diabetes.
2022cited by 5position: contributordoi
Early Trajectory of Estimated Glomerular Filtration Rate and Long-term Advanced Kidney and Cardiovascular Complications in Type 1 Diabetes.
2022cited by 5position: contributordoi
Left Ventricular Structure, Tissue Composition, and Aortic Distensibility in the Diabetes Control and Complications Trial/Epidemiology of Diabetes Intervention and Complications
The American Journal of Cardiology 2022cited by 2position: contributordoi
Cognitive performance declines in older adults with type 1 diabetes: results from 32 years of follow-up in the DCCT and EDIC Study
The Lancet Diabetes & Endocrinology 2021cited by 127position: lastdoi
Understanding Metabolic Memory: The Prolonged Influence of Glycemia During the Diabetes Control and Complications Trial (DCCT) on Future Risks of Complications During the Study of the Epidemiology of Diabetes Interventions and Complications (EDIC).
2021cited by 94position: contributordoi
Utility of using electrocardiogram measures of heart rate variability as a measure of cardiovascular autonomic neuropathy in type 1 diabetes patients
Journal of Diabetes Investigation 2021cited by 51position: middledoi
Baseline Predictors of Glycemic Worsening in Youth and Adults With Impaired Glucose Tolerance or Recently Diagnosed Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
Diabetes Care 2021cited by 44position: middledoi
The Beneficial Effects of Earlier Versus Later Implementation of Intensive Therapy in Type 1 Diabetes.
2021cited by 43position: contributordoi
Obstructive Sleep Apnea, Glucose Tolerance, and β-Cell Function in Adults With Prediabetes or Untreated Type 2 Diabetes in the Restoring Insulin Secretion (RISE) Study
Diabetes Care 2021cited by 26position: middledoi
Associations of Microvascular Complications With the Risk of Cardiovascular Disease in Type 1 Diabetes.
2021cited by 24position: contributordoi
Shape of the OGTT glucose response curve: relationship with β-cell function and differences by sex, race, and BMI in adults with early type 2 diabetes treated with metformin.
2021cited by 20position: contributordoi
Association of Baseline Characteristics With Insulin Sensitivity and β-Cell Function in the Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness (GRADE) Study Cohort.
2021cited by 19position: contributordoi

Grants

No grants ingested yet.

Frequent collaborators

· 37 papers (2019–2026) · 23 papers (2019–2024)Barbara H. Braffett · Milken Institute20 papers (2019–2024) · 13 papers (2019–2024)Rose Gubitosi‐Klug · University School13 papers (2019–2024)Bernard Zinman · Lunenfeld-Tanenbaum Research Institute10 papers (2014–2023)William H. Herman · VA Eastern Colorado Health Care System8 papers (2019–2024) · 8 papers (2019–2024)Ionut Bebu · University of Colorado Denver8 papers (2019–2022)Gayle M. Lorenzi · University of Iowa7 papers (2014–2022)David Fitchett · St. Michael's Hospital6 papers (2014–2017) · 6 papers (2019–2024)Rodica Pop-Busui · Stanford University6 papers (2019–2024)Silvio E. Inzucchi · Yale University6 papers (2014–2017)Christoph Wanner · Smart Material (Germany)6 papers (2014–2017)Jye‐Yu C. Backlund · George Washington University5 papers (2015–2022)Bruce A. Perkins · Sinai Health System5 papers (2019–2022)Odd Erik Johansen · Société d'Étude de l'Environnement (Switzerland)5 papers (2014–2017)John B. Buse · University of North Carolina at Chapel Hill4 papers (2015–2018)Rury R. Holman · Indiana University Health4 papers (2015–2018)